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Evaluation of Silver Ion-Releasing Scaffolds in a 3D
Coculture System of MRSA and Human Adipose-Derived
Stem Cells for Their Potential Use in Treatment
or Prevention of Osteomyelitis
Mahsa Mohiti-Asli, PhD,1 Casey Molina, BS,1 Thamonwan Diteepeng, BS,2
Behnam Pourdeyhimi, PhD,3 and Elizabeth G. Loboa, PhD1,4
Bone infection, also called osteomyelitis, can result when bacteria invade a bone. Treatment of osteomyelitis
usually requires surgical debridement and prolonged antimicrobial therapy. The rising incidence of infection
with multidrug-resistant bacteria, in particular methicillin-resistant staphylococcus aureus (MRSA), however,
limits the antimicrobial treatment options available. Silver is well known for its antimicrobial properties and is
highly toxic to a wide range of microorganisms. We previously reported our development of biocompatible,
biodegradable, nanofibrous scaffolds that released silver ions in a controlled manner. The objective of this study
was to determine the efficacy of these scaffolds in treating or preventing osteomyelitis. To achieve this
objective, antimicrobial efficacy was determined using a 3D coculture system of human adipose-derived stem
cells (hASC) and MRSA. Human ASC were seeded on the scaffolds and induced to undergo osteogenic
differentiation in both the absence and presence of MRSA. Our results indicated that the silver ion-releasing
scaffolds not only inhibited biofilm formation, but also supported osteogenesis of hASC. Our findings suggest
that these biocompatible, degradable, silver ion-releasing scaffolds can be used at an infection site to treat
osteomyelitis and/or to coat bone implants as a preventative measure against infection postsurgery.
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Introduction
Osteomyelitis is a debilitating infectious diseasecharacterized by severe inflammation and progressive
bone destruction.1 It can cause severe infection in bone, bone
marrow, or surrounding soft tissue. Osteomyelitis usually
occurs as a result of hematogenous spread of microorganisms
to the bone from an indirect entry, such as contiguous in-
fection or from an open wound caused by bone surgery or
joint replacement.2 The most common bacterium that has
been isolated from more than half of the reported osteomy-
elitis cases is Staphylococcus aureus.1 Treatment of bone
infection is primarily through surgical debridement and re-
moval of all necrotic tissue, followed by long-term admin-
istration of intravenous and oral antibiotics.3,4 Typically, high
doses of antibiotics are needed to achieve an effective ther-
apeutic drug concentration in the bone. This can cause sys-
temic toxicity.5 Despite continuing advances in surgical
procedures and use of antibiotics, up to 30% of treatments fail
and patients with osteomyelitis develop chronic infections.6
This could be due to avascularity of developing sequestra,
inhibiting the ability of antibiotics and inflammatory cells to
reach the infected site.1 Alternative strategies are, therefore,
critical to investigate.
Controlled antimicrobial release systems are new strategies
to prevent and treat chronic osteomyelitis. Such systems enable
administration of higher antimicrobial concentrations at the
site of infection for prolonged duration without systemic
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toxicity. Some systems have been developed for local delivery
of different antibiotics to infected bone, predominantly im-
plementing a biomaterial that can release antibiotics. Bioma-
terials used for this purpose usually consist of a porous scaffold
containing an osteoconductive compound such as hydroxyap-
atite,7 calcium phosphate,8 and/or recombinant human bone
morphogenetic protein-2.9 The most common antibiotic used
in such local delivery platforms is vancomycin. Previous in-
vestigators have shown that scaffolds doped with vancomycin
can inhibit the growth of staphylococcus aureus.9–11 However,
due to the vast increase in multidrug-resistant Staphylococcus
aureus strains, utilization of antibiotics is becoming increas-
ingly unsuccessful.
Silver is a broad-spectrum biocide that is toxic to a wide
range of microorganisms. Previous investigators have eval-
uated local delivery of silver to an infection site.12 Studies
evaluating scaffolds for bone tissue engineering applications
in the presence of bacteria have predominantly focused on
incorporation of silver nanoparticles in an osteoconductive
scaffold. Marsich et al. added silver nanoparticles to an al-
ginate/hydroxyapatite composite through an adsorption pro-
cess.13 Their in vitro analyses were carried out for 7 days and
indicated that the release of silver did not inhibit the prolif-
eration of osteoblasts. In another study, silver nanoparticles
were added to chitosan/hydroxyapatite scaffolds through a
reduction phenomenon using functional groups of chitosan.14
Cytotoxicity analyses of the scaffolds after 24 h showed that
the scaffolds were not toxic to rat osteoprogenitor cells or
human osteosarcoma cells. Although the short-term cell cul-
ture analyses in these studies,13,14 and other similar studies15,16
showed no cytotoxicity associated with the release of silver
nanoparticles, concerns remain about the long-term effects
of silver nanoparticles on host mammalian cells.17 Some
studies have shown that the very small size of nanoparticles
allows them to diffuse within the cellular plasma membrane
and interfere with a variety of cellular mechanisms.18,19
Thus, in recent years, the Food and Drug Administration
(FDA) and others20–22 have expressed concern about the
use of silver nanoparticles.
Recently, we reported development and validation of
scaffolds capable of releasing silver ions at a controlled rate
without the use of silver nanoparticles.23 The scaffolds are
comprised of polylactic acid (PLA) nanofibers coated with a
proprietary polymer containing silver nitrate ( Silvadur ET;
Dow Chemical Company). This nanofibrous delivery plat-
form is biocompatible and biodegradable, eliminating the
need for removal surgery. We previously showed that these
scaffolds were effective in inhibiting growth of Staphylo-
coccus aureus.23 The goal of this study was to evaluate
efficacy of these scaffolds against multidrug-resistant Sta-
phylococcus aureus (MRSA) and potential utilization of
these materials for bone tissue engineering and/or bone re-
generation in an environment contaminated with MRSA.
To evaluate the potential use of these antimicrobial scaf-
folds for osteomyelitis and/or bone tissue engineering in in-
fected wound sites, osteogenesis of human adipose-derived
stem cells (hASC) seeded on these scaffolds was determined.
To better mimic the osteomyelitis state in vitro, a coculture
system of hASC and MRSA was developed by modifying a
previously published coculture technique used for evaluation
of wound dressings.24 In particular, our system allows for
simultaneous evaluation of the scaffolds’ antimicrobial
properties, while also assessing their ability to support oste-
ogenic differentiation of human stem cells. As opposed to
previous studies, which evaluated antimicrobial and osteo-
genic differentiation analyses of their materials in separate
cell culture experiments,15,16 our system allows for in vitro
analyses in an environment that includes interactions of hu-
man stem cells with MRSA bacteria in the same culture
system. This newlymodified coculture system also provides a
platform for evaluation of other controlled release systems for
their efficacy in addressing osteomyelitis. To our knowledge,
this is the first study to evaluate a biomaterial for its ability to
simultaneously promote osteogenic differentiation of human
stem cells, while also exhibiting antimicrobial efficacy in a
coculture system comprised of both hASC and MRSA.
Materials and Methods
Fabrication of antimicrobial scaffolds
PLA nanofibrous scaffolds were fabricated as previously
described23 Briefly, PLA (MW: 70,000 g mol-1) was dis-
solved in chloroform and dimethylformamide (Sigma) at a
ratio of 3:1 to create an 11% polymeric solution. The solution
was stirred at 80C for 4 h and then electrospun in a custom
electrospinning system. The electrospun PLA nanofibers
were immersed for 1 h in a diluted solution of Silvadur ET
containing 31.25mg/mL silver. Nanofibrous scaffolds were
then dried under a fume hood for 24 h to form a thin antimi-
crobial coating. Coated scaffolds were cut into circles (1 cm
diameter) and sterilized with ethylene oxide gas for 12 h.
Culture of hASC
Human adipose tissue was obtained from a voluntary li-
posuction procedure performed on a 36-year-old Caucasian
female in accordance with an approved IRB protocol (IRB-
04-1622) at the University of North Carolina, Chapel Hill.
hASC were isolated from the adipose tissue as previously
reported by our laboratory.25,26 Human ASC were expanded
to passage 3 and maintained in complete growth medium
(CGM) (alpha minimum essential medium [a-MEM]
[88%], fetal bovine serum [FBS, 10%], L-glutamine [1%],
and penicillin/streptomycin [1%]) in 75-cm2 tissue culture
flasks until they reached 80% confluency (approximately
10 days). Human ASC were then trypsinized and suspended
in a predetermined volume of CGM to achieve the con-
centration of 250,000 cells mL-1. Eighty microliters of the
prepared cell suspension was added on top of each scaffold.
Culture of MRSA
MRSA bacteria (ATCC BAA-44) were streaked for
isolation on a soybean casein digest agar plate (Fisher Sci-
entific). The agar plate was incubated (37C, 5% CO2)
overnight and then a single isolated MRSA colony was se-
lected and used to inoculate 5mL of Muller-Hinton (MH)
broth (Difco Laboratories). After culture overnight, the
bacterial concentration was determined by measurement
of the optical density of the bacterial suspension using a
UV-Vis spectrophotometer (BioMate3, Thermo Electron
Corporation) at a wavelength of 600 nm. The bacterial con-
centration was then adjusted by serial dilution to acquire the
concentrations utilized for the following experiments.
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Evaluation of antimicrobial efficacy of silver-releasing
scaffolds against MRSA: AATCC 147 protocol
The standard AATCC 147 test, also known as the ‘‘parallel
streak method,’’ was utilized to evaluate the antimicrobial
efficacy of the silver-releasing scaffolds against MRSA. A
1.5 · 108 CFU/mL (0.5 McFarland) suspension of MRSA
bacteria in phosphate-buffered saline (PBS) was prepared and
spread over each agar plate using a sterile swab to prepare
bacterial lawns. Silver-releasing scaffolds (1.6 cm diameter)
were placed in the center of the bacterial lawn and incubated
overnight. Bactericidal activity was then visually assessed to
determine the zone of inhibition around the scaffold to eval-
uate antimicrobial efficacy of the scaffolds against MRSA.
Coculture system of hASC with MRSA
Osteogenic differentiation of hASC seeded on the antimi-
crobial scaffolds in the presence of MRSA was evaluated in a
3D coculture system using an adaptation of our previously
published technique.24 Briefly, antimicrobial scaffolds were
seeded with hASC at a density of 2· 104 hASC per square
centimeter. The cell-seeded scaffolds were placed into the
separate wells of 24-well plates. One microliter of CGM
without penicillin/streptomycin was pipetted into each well
and the plates were incubated for 24 h. The CGM was then
replaced with 1mL osteogenic differentiation medium (ODM)
(CGMwithout antibiotics and supplemented with 5· 10-5 mM
ascorbic acid, 0.1· 10-6 M dexamethasone, and 10-2 M b-
glycerophosphate) containing 10 CFU/mL MRSA bacteria.
Scaffolds seeded with hASC and inoculated with MRSA were
then incubated for 2 weeks. Daily, the mediumwas pipetted up
and down several times, to ensure bacteriawerewell suspended
in the medium, and one-half of the bacterial suspension was
then taken out of the plates and replaced with fresh ODM.
Separate experiments with only hASC or MRSA bacteria
were also performed to better interpret and elucidate the results
of the coculture system. Pure PLA scaffolds (containing no
silver) were used as controls for all experimental conditions.
Monitoring MRSA growth in coculture system
For daily evaluation of the bacterial concentration, har-
vested bacterial suspensions were diluted multiple times, and
spread on agar plates. Agar plates were incubated overnight to
allow bacterial colonies to grow and become visible to the
naked eye for counting.
Monitoring osteogenic differentiation of hASC
in a coculture system
Osteogenic differentiation of hASC seeded on the scaf-
folds was determined by quantification of total calcium
accretion, a measure of mineral deposition, on days 7 and
14. Scaffolds were washed three times with 1· PBS and
calcium was solubilized by overnight immersion of scaf-
folds in 0.5 N hydrogen chloride (HCl). The supernatants
were collected and assayed using the Calcium LiquiColor
Kit (Stanbio Laboratory). To perform the assay, 10 mL of
supernatants were mixed with 200 mL of assay reagent so-
lution as per the manufacturer’s instructions for microplate
analyses, and absorbance read at 550 nm using a microplate
reader (TECAN GENios). Calcium chloride (CaCl2) was
used to generate a standard curve as per the manufacturer’s
instructions. The standard curve was used to determine
sample calcium concentration. Calcium accretion data were
normalized to total DNA using the DNA Hoechst fluores-
cence assay.
To measure the total DNA, scaffolds were washed at least
three times with PBS to confirm that the bacteria were
detached from the scaffolds. Samples were vortexed during
the washing process to assist with the detachment of bacteria.
To verify that all bacteria were washed out from the scaffolds,
the PBS solution from the last wash was used for bacterial
analysis to confirm no bacteria were present in the PBS from
the last wash. Once this was confirmed, the amount of DNA in
each nanofibrous scaffold was then measured with DNA-
binding dye, Hoechst 33258, in microplate format after
overnight digestion at 60C in 2.5U/mL papain in PBS with
5mM ethylenediaminetetraacetic acid and 5mM cysteine
HCl (all reagents from Sigma). Fluorescence wasmeasured at
an excitation wavelength of 352 nm and emission wavelength
of 461 nm on a microplate reader. A DNA standard curve
was generated using DNA derived from calf thymus (Sigma)
and DNA concentration was calculated as a function of
fluorescence.
Calcium accretion was also visualized by staining cal-
cium deposits using Alizarin Red S (Acros Organics).
Scaffolds were harvested at 7 and 14 days and placed in 10%
formalin for 30min to fix cells adhered to the scaffolds. Cell-
seeded scaffolds were then stained with 2% Alizarin Red S
(pH 4.2) for 3min and rinsed with deionized water three
times to remove any unbound stain. Light microscopy im-
ages were captured with a Leica EZ 4D Digital Dissecting
Scope.
FIG. 1. Antimicrobial efficacy of control
PLA scaffolds (a) and silver-releasing scaf-
folds (b) against MRSA bacteria as evalu-
ated by the AATCC 147 test. MRSA,
Methicillin-resistant staphylococcus aureus;
PLA, polylactic acid. Color images available
online at www.liebertpub.com/tea
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Microscopy analyses
Surface topography of the scaffolds was evaluated using
scanning electron microscopy (SEM) (FESEM JEOL 6400 F)
at 15 kV accelerating voltage. Nanofibrous scaffolds were
fixed in 10% buffered formalin for 30min then dehydrated in
a graded series of increasing ethanol concentrations (50–
100%). Dehydrated scaffolds were chemically dried by im-
mersion in hexamethyldisilazane for 15min then air dried
overnight in a fume hood. Scaffolds were then sputter coated
with gold to visualize surface morphology using SEM.
Statistical analyses
All experiments were performed using at least three tech-
nical replicates. Statistical analyses were performed using
SPSS 14.0. Data were analyzed using Duncan test with
p-values less than 0.05 considered statistically significant.
Results
Evaluation of antimicrobial efficacy of silver-releasing
scaffolds against MRSA—AATCC 147 protocol
After overnight incubation of the silver-releasing scaffolds
on MRSA-inoculated agar plates, a clear zone of inhibition
was observed around the scaffolds confirming effectiveness
of these materials against MRSA (Fig. 1).
Monitoring MRSA growth in hASC/MRSA
coculture system
Concentration of MRSA in cultures with control PLA (i.e.,
pure PLA with no silver) scaffolds, either acellular or seeded
with hASC, increased rapidly by 8 log one day after culture
(Fig. 2). Growth of MRSA in these cultures continued with a
slower rate thereafter. Growth of MRSA in cultures with
silver-releasing scaffolds was significantly decreased for the
first 5 days. The bacterial concentration displayed the largest
growth on day 6 and then continued the trend of increasing
growth, although at a diminished rate (Fig. 2).
Scanning electron microscopy analyses of scaffolds
Scanning electron microscopy revealed growth of MRSA
over 2weeks between the fibers of both control PLAand silver-
releasing scaffolds (Fig. 3). The images showed formation of a
biofilm, a dense layer of bacteria, on both cell-seeded and
acellular PLA scaffolds (Fig. 3). However, although MRSA
also grew in the silver-releasing scaffolds, no evidence of
biofilm formation was observed on these scaffolds.
Osteogenic differentiation of hASC in hASC/MRSA
coculture system
To qualitatively assess cell-mediated calcium accretion,
calcium deposition was visualized using Alizarin Red S on
days 7 and 14 (Fig. 4). After 7 days of culture, minerali-
zation occurred for all samples. On day 14, significant in-
creases in mineralization were noted for all samples (Fig. 4).
Mineralization of hASC was quantified on days 7 and 14
for total calcium content in the scaffolds (Fig. 5). Miner-
alization of hASC seeded on silver-releasing scaffolds was
not significantly different from that of hASC seeded on
control PLA scaffolds after 7 and 14 days. With the intro-
duction of MRSA to the cultures, mineralization of hASC
seeded on control PLA scaffolds significantly decreased
on day 7. In contrast, addition of MRSA to cultures with
FIG. 2. Growth of MRSA bacteria over 2 weeks when cul-
tured with acellular or hASC-seeded PLA and silver-releasing
PLA (Ag/PLA) scaffolds. hASC, adipose-derived stem cell.
Color images available online at www.liebertpub.com/tea
FIG. 3. Scanning electron microscopy
photographs of scaffolds in MRSA suspen-
sions after 2 weeks. (a) hASC-seeded
control PLA (no silver) scaffolds, (b) hASC-
seeded silver-releasing scaffolds, (c) acellu-
lar control PLA scaffolds (no hASC and no
silver), and (d) acellular silver-releasing
scaffolds. Solid arrows point to hASC and
dashed arrows point to MRSA bacteria.
Dense layer of MRSA bacteria, representing
formation of biofilm, observed on both
hASC-seeded and acellular PLA scaffolds,
but not hASC-seeded or acellular silver-
releasing scaffolds.
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silver-releasing scaffolds resulted in no significant differ-
ence in mineralization at this time point. By day 14, calcium
accretion was significantly decreased for hASC on both
scaffolds in the presence of MRSA relative to hASC oste-
ogenic differentiation and calcium accretion in cultures
without MRSA. However, cell-mediated calcium accretion
was significantly higher for hASC seeded on antimicrobial
scaffolds relative to those on control PLA scaffolds (Fig. 5).
Discussion
In this study, the efficacy of a silver-releasing scaffold was
evaluated for osteomyelitis using a 3D coculture of hASC and
MRSA. We previously developed and evaluated similar
scaffolds for skin tissue engineering applications.23 We found
in that study that a silver concentration of 31.25mg/mL in the
coating solution allowed for enough silver ion release to in-
hibit the growth of S. aureus (methicillin-resistant S. aureus
not evaluated in that study) without causing cytotoxicity
to human skin cells.23 The same silver concentration was
incorporated in the scaffolds used for this study and their
effectiveness against MRSA was evaluated. Our results
confirmed that these scaffolds were capable of both inhibiting
growth of and killing MRSA, a superbug of increasing threat
to patients with osteomyelitis.
To evaluate the potential efficacy of these scaffolds for
osteomyelitis, a 3D coculture system of hASC and MRSA
was designed based on a modification of our previously
published technique.24 In this system, both osteogenesis of
hASC and growth of MRSA were simultaneously evaluated.
We found that the silver-releasing scaffolds were capable of
significantly delaying the growth of MRSA (Fig. 2). Spe-
cifically, the bacterial growth rate was significantly slower
for the first 5 days. Management of bacterial growth in the
early stages of osteomyelitis is critical as it can decrease
chances of developing chronic osteomyelitis. Although the
bacterial growth in cultures with silver-releasing scaffolds
was not fully inhibited, likely due to the high concentration
of bacteria relative to the size of the scaffold used, the
materials appeared to inhibit biofilm formation (Fig. 3).
Formation of a biofilm allows for immune evasion and re-
sistance to antimicrobial agents.27 When such biofilms are
formed on bones as occurs with osteomyelitis, the gold
standard of care is to surgically remove the bone.1
It is essential to ensure that scaffolds used to deliver an-
timicrobial agents to the infected bone site do not cause cy-
totoxicity of human stem and bone cells and do not inhibit
osteogenesis. Our coculture system allowed assessment of the
antimicrobial efficacy of our scaffolds in an in vitro envi-
ronment that resembles osteomyelitis. Both Alizarin Red
staining and calcium deposition quantification results con-
firmed that the silver-releasing scaffolds allowed for contin-
ued osteogenesis of hASC on the antimicrobial scaffolds, an
outcome that was not achieved using pure PLA scaffolds.
Future studies could expand upon this work to evaluate re-
lease of inflammatory mediators, such as interleukin-1beta
(IL-1b), interleukin-6 (IL-6), interleukin-8 (IL-8) and/or tu-
mor necrosis factor alpha (TNF-a).
This is the first study to develop a 3D coculture system for
evaluation of antimicrobial scaffolds for osteomyelitis. Our
findings suggest the potential use of our silver-releasing
scaffolds in treating bone infection, for bone tissue engi-
neering in an infected wound site, and/or as a coating on
bone implants to prevent osteomyelitis.
FIG. 4. Alizarin red stain-
ing of hASCs-seeded scaf-
folds in cultures with or
without the presence of
MRSA after 7 and 14 days.
Scale bar is 3mm. Control
PLA = polylactic acid scaf-
folds without silver; Cells =
hASC; Bact =MRSA;
Anti = silver-releasing
scaffold. Color images
available online at www
.liebertpub.com/tea
FIG. 5. Calcium accretion quantification of hASC (Cell)
seeded on PLA and silver-releasing PLA (Ag/PLA) scaffolds
and induced to undergo osteogenic differentiation in cultures
with or without the presence of MRSA (Bact). Columns with
different letters indicate significant difference ( p< 0.05).
Color images available online at www.liebertpub.com/tea
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